A Phase 2 interventional study of ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Completed at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-10-31.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 2, and was the 6th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 2+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 77 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 3 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
17 studies in Dermatitis, Atopic by Incyte Corporation: 2 open now, 3 under way, 1 of them phase 3. Of 14 finished, 10 (71%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Incyte Corporation, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 6th registered.
Incyte Corporation’s Dermatitis, Atopic studies by the year they started, since 2017.
1 of the studies testing ruxolitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661979Wake Forest University Health SciencesOpzelura Experience Study | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 17 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participant had significant flares or unstable course in AD.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ruxolitinib cream 1.5% will be applied twice daily as a thin film.
Drug: ruxolitinib cream
ruxolitinib cream 1.5% will be applied twice daily as a thin film
Also known as: INCB018424
Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
Time frame: Baseline; Day 2
Change From Baseline in the Modified Peak-Pruritus Numerical Rating Scale (mPP-NRS) Score (Current Itch Intensity) at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Change From Baseline in the PP-NRS Score From Day 3 Through Day 29 (24-hour Recall Period After First Application)
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
Time frame: Baseline; Day 3 through Day 29
Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments). Confidence intervals were calculated using the Clopper-Pearson method.
Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Percentage of Participants Achieving at Least a 1-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
Time frame: Baseline; Day 2 through Day 29
Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the mPP-NRS Score at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
Time frame: Baseline; Day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Percentage of Participants Achieving at Least a 2-grade Decrease From Baseline in the PP-NRS Score From Day 2 Through Day 29
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
Time frame: Baseline; Day 2 through Day 29
Time to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline )
The MCID corresponds to an achievement of a ≥2-grade reduction in PP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
Time frame: from Baseline up to Day 29
Time to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline)
The MCID corresponds to an achievement of a ≥2-grade reduction in mPP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
Time frame: Baseline; Day 1
Change From Baseline in Investigator Global Assessment (IGA) at Day 8, Day 15, and Day 29
The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Days 8, 15, and 29
Percentage of Participants Achieving Investigator Global Assessment-Treatment Success (IGA-TS) (Score of 0 or 1 in IGA With a ≥2-grade Reduction From Baseline) at Day 8, Day 15, and Day 29
The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade reduction from Baseline. The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
Time frame: Baseline; Days 8, 15, and 29
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose.
Time frame: up to Day 43
Number of Participants With Any Grade 3 or Higher TEAE
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose. The severity of AEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
Time frame: up to Day 43
This study was conducted at 1 study center in Canada.
| Milestone | Ruxolitinib 1.5% Cream BID |
|---|---|
| Started | 49 |
| Intent-to-treat population | 46 |
| Completed | 44 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Dosed, but did not complete run-in period | 3 |
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
| scores on a scale | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 6.72 ± 1.363 |
| Change from Baseline at Day 2 | -3.37 ± 1.847 |
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
| scores on a scale | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 6.4 ± 1.72 |
| Change from Baseline at 15 minutes postdose | -2.3 ± 2.34 |
| Change from Baseline at 30 minutes postdose | -3.0 ± 2.38 |
| Change from Baseline at 1 hour postdose | -3.3 ± 2.45 |
| Change from Baseline at 2 hours postdose | -3.8 ± 2.16 |
| Change from Baseline at 4 hours postdose | -4.2 ± 2.12 |
| Change from Baseline at 6 hours postdose | -4.2 ± 2.04 |
| Change from Baseline at 12 hours postdose | -3.1 ± 2.00 |
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
| scores on a scale | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 6.72 ± 1.363 |
| Change from Baseline at Day 3 | -3.78 ± 1.775 |
| Change from Baseline at Day 4 | -4.00 ± 1.760 |
| Change from Baseline at Day 5 | -4.20 ± 1.875 |
| Change from Baseline at Day 6 | -4.58 ± 1.935 |
| Change from Baseline at Day 7 | -4.78 ± 1.755 |
| Change from Baseline at Day 8 | -4.91 ± 1.832 |
| Change from Baseline at Day 9 | -4.92 ± 1.890 |
| Change from Baseline at Day 10 | -5.00 ± 1.762 |
| Change from Baseline at Day 11 | -5.19 ± 1.606 |
| Change from Baseline at Day 12 | -5.19 ± 1.722 |
| Change from Baseline at Day 13 | -5.03 ± 1.907 |
| Change from Baseline at Day 14 | -5.10 ± 1.745 |
| Change from Baseline at Day 15 | -5.03 ± 1.805 |
| Change from Baseline at Day 16 | -5.30 ± 1.680 |
| Change from Baseline at Day 17 | -5.28 ± 1.510 |
| Change from Baseline at Day 18 | -5.34 ± 1.826 |
| Change from Baseline at Day 19 | -5.37 ± 1.739 |
| Change from Baseline at Day 20 | -5.40 ± 1.759 |
| Change from Baseline at Day 21 | -5.52 ± 1.692 |
| Change from Baseline at Day 22 | -5.56 ± 1.726 |
| Change from Baseline at Day 23 | -5.50 ± 1.598 |
| Change from Baseline at Day 24 | -5.28 ± 1.773 |
| Change from Baseline at Day 25 | -5.65 ± 1.629 |
| Change from Baseline at Day 26 | -5.68 ± 1.585 |
| Change from Baseline at Day 27 | -5.69 ± 1.689 |
| Change from Baseline at Day 28 | -5.39 ± 1.845 |
| Change from Baseline at Day 29 | -5.68 ± 1.595 |
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments). Confidence intervals were calculated using the Clopper-Pearson method.
| percentage of participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| 15 minutes postdose | 82.6 (68.6 to 92.2) |
| 30 minutes postdose | 89.1 (76.4 to 96.4) |
| 1 hour postdose | 89.1 (76.4 to 96.4) |
| 2 hours postdose | 97.8 (88.5 to 99.9) |
| 4 hours postdose | 100.0 (92.3 to 100.0) |
| 6 hours postdose | 97.8 (88.5 to 99.9) |
| 12 hours postdose | 90.7 (77.9 to 97.4) |
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
| percentage of participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Day 2 | 93.3 (81.7 to 98.6) |
| Day 3 | 95.6 (84.9 to 99.5) |
| Day 4 | 97.8 (88.2 to 99.9) |
| Day 5 | 97.8 (88.5 to 99.9) |
| Day 6 | 97.8 (88.2 to 99.9) |
| Day 7 | 97.8 (88.5 to 99.9) |
| Day 8 | 97.8 (88.2 to 99.9) |
| Day 9 | 97.8 (88.2 to 99.9) |
| Day 10 | 97.7 (88.0 to 99.9) |
| Day 11 | 100.0 (92.1 to 100.0) |
| Day 12 | 100.0 (92.1 to 100.0) |
| Day 13 | 100.0 (92.1 to 100.0) |
| Day 14 | 97.8 (88.2 to 99.9) |
| Day 15 | 100.0 (92.1 to 100.0) |
| Day 16 | 100.0 (92.1 to 100.0) |
| Day 17 | 100.0 (92.1 to 100.0) |
| Day 18 | 100.0 (92.1 to 100.0) |
| Day 19 | 97.8 (88.2 to 99.9) |
| Day 20 | 97.7 (87.7 to 99.9) |
| Day 21 | 100.0 (92.1 to 100.0) |
| Day 22 | 100.0 (92.0 to 100.0) |
| Day 23 | 100.0 (92.1 to 100.0) |
| Day 24 | 97.8 (88.2 to 99.9) |
| Day 25 | 100.0 (92.1 to 100.0) |
| Day 26 | 100.0 (92.1 to 100.0) |
| Day 27 | 100.0 (92.0 to 100.0) |
| Day 28 | 97.7 (88.0 to 99.9) |
| Day 29 | 100.0 (91.6 to 100.0) |
On Day 1, participants were asked to evaluate the current intensity of their itch at the time of assessment (i.e., prior to the morning study drug application, and 15 and 30 minutes and 1, 2, 4, 6, and 12 hours after the morning study drug application; the 12-hour evaluation occurred prior to the second daily study drug application) on a scale from 0 to 10, with 0 indicating no itch and 10 indicating the worst imaginable itch. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
| percentage of participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| 15 minutes postdose | 58.7 (43.2 to 73.0) |
| 30 minutes postdose | 67.4 (52.0 to 80.5) |
| 1 hour postdose | 71.7 (56.5 to 84.0) |
| 2 hours postdose | 91.3 (79.2 to 97.6) |
| 4 hours postdose | 95.7 (85.2 to 99.5) |
| 6 hours postdose | 93.5 (82.1 to 98.6) |
| 12 hours postdose | 76.7 (61.4 to 88.2) |
The intensity of pruritus (itch) was recorded daily using the PP-NRS (24-hour recall period). Participants were asked to assign a numerical score representing their itch at the worst moment during the previous 24 hours on a scale of 0 to 10, with 0 being no itch and 10 being the worst itch imaginable. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
| percentage of participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Day 2 | 71.1 (55.7 to 83.6) |
| Day 3 | 82.2 (67.9 to 92.0) |
| Day 4 | 84.4 (70.5 to 93.5) |
| Day 5 | 87.0 (73.7 to 95.1) |
| Day 6 | 91.1 (78.8 to 97.5) |
| Day 7 | 95.7 (85.2 to 99.5) |
| Day 8 | 93.3 (81.7 to 98.6) |
| Day 9 | 95.6 (84.9 to 99.5) |
| Day 10 | 95.5 (84.5 to 99.4) |
| Day 11 | 97.8 (88.2 to 99.9) |
| Day 12 | 97.8 (88.2 to 99.9) |
| Day 13 | 95.6 (84.9 to 99.5) |
| Day 14 | 97.8 (88.2 to 99.9) |
| Day 15 | 97.8 (88.2 to 99.9) |
| Day 16 | 100.0 (92.1 to 100.0) |
| Day 17 | 97.8 (88.2 to 99.9) |
| Day 18 | 95.6 (84.9 to 99.5) |
| Day 19 | 95.6 (84.9 to 99.5) |
| Day 20 | 97.7 (87.7 to 99.9) |
| Day 21 | 97.8 (88.2 to 99.9) |
| Day 22 | 97.7 (88.0 to 99.9) |
| Day 23 | 100.0 (92.1 to 100.0) |
| Day 24 | 95.6 (84.9 to 99.5) |
| Day 25 | 100.0 (92.1 to 100.0) |
| Day 26 | 100.0 (92.1 to 100.0) |
| Day 27 | 97.7 (88.0 to 99.9) |
| Day 28 | 95.5 (84.5 to 99.4) |
| Day 29 | 97.6 (87.4 to 99.9) |
The MCID corresponds to an achievement of a ≥2-grade reduction in PP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the average of all non-missing PP-NRS scores reported during the 7-day run-in period.
| days | Ruxolitinib 1.5% Cream BID |
|---|---|
| Time to Minimal Clinically Important Difference (MCID) for PP-NRS (≥2-grade Reduction in PP-NRS From Baseline ) | 1.6 ± 1.42 |
The MCID corresponds to an achievement of a ≥2-grade reduction in mPP-NRS from Baseline. The time to MCID was defined as the time from the date (time) of the first dose to the date (time) of the first occurrence of MCID. Baseline was defined as the last non-missing assessment before or on Day 1 and prior to the first application of study drug (including unscheduled assessments).
| hours | Ruxolitinib 1.5% Cream BID |
|---|---|
| Time to MCID for mPP-NRS (≥2-grade Reduction in mPP-NRS From Baseline) | 0.817 ± 0.9788 |
The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| scores on a scale | Ruxolitinib 1.5% Cream BID |
|---|---|
| Baseline | 2.9 ± 0.31 |
| Change from Baseline a Day 8 | -1.4 ± 0.73 |
| Change from Baseline at Day 15 | -2.0 ± 0.87 |
| Change from Baseline at Day 29 | -2.2 ± 0.90 |
The IGA-TS is defined as an IGA score of 0 or 1 with a ≥2-grade reduction from Baseline. The IGA of the current state of the disease is a 5-point morphological assessment of overall disease severity. 0, clear: no erythema or induration/papulation, no oozing/crusting; there may be minor residual discoloration. 1, almost clear: there may be trace faint pink erythema with almost no induration/papulation and no oozing/crusting. 2, mild: there may be faint pink erythema with mild induration/papulation and no oozing/crusting. 3, moderate: there may be pink-red erythema with moderate induration/papulation, and there may be some oozing/crusting. 4, severe: there may be deep or bright red erythema with severe induration/papulation and with oozing/crusting.
| percentage of participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Day 8 | 45.5 (30.4 to 61.2) |
| Day 15 | 71.1 (55.7 to 83.6) |
| Day 29 | 77.3 (62.2 to 88.5) |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose.
| participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 15 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose. The severity of AEs were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.
| participants | Ruxolitinib 1.5% Cream BID |
|---|---|
| Number of Participants With Any Grade 3 or Higher TEAE | 0 |
Collected over up to Day 43. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib 1.5% Cream BID | 0/49 (0%) | 0/49 (0%) | 15/49 (30.6%) |
| Event | Ruxolitinib 1.5% Cream BID |
|---|---|
| COVID-19Infections and infestations | 3/49 |
| Back painMusculoskeletal and connective tissue disorders | 2/49 |
| HeadacheNervous system disorders | 2/49 |
| NasopharyngitisInfections and infestations | 2/49 |
| Upper respiratory tract infectionInfections and infestations | 2/49 |
| AcneSkin and subcutaneous tissue disorders | 1/49 |
| ConcussionInjury, poisoning and procedural complications | 1/49 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/49 |
| Eye pruritusEye disorders | 1/49 |
| GastroenteritisInfections and infestations | 1/49 |
| Age, Continuous(years) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Mean | 35.6 ± 14.77 |
| Sex: Female, Male(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Female | 35 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 45 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ruxolitinib 1.5% Cream BID |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 42 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Oct 2021 to primary completion in Nov 2022, 13 months.
Results were first posted in Oct 2023, 11 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib